Published in Brain on February 04, 2007
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
Development, maintenance and disruption of the blood-brain barrier. Nat Med (2013) 2.62
Aquaporin 4 and neuromyelitis optica. Lancet Neurol (2012) 2.58
Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol (2014) 2.37
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol (2009) 1.88
Oligodendrocytes: biology and pathology. Acta Neuropathol (2009) 1.81
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology (2014) 1.80
Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (2013) 1.79
Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol (2011) 1.72
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics (2010) 1.60
The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol (2014) 1.60
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A (2011) 1.60
Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem (2012) 1.55
Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54
Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci (2015) 1.53
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology (2009) 1.52
Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J (2011) 1.50
Aquaporin 4 molecular mimicry and implications for neuromyelitis optica. J Neuroimmunol (2013) 1.42
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS One (2011) 1.38
Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol (2010) 1.37
Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology (2012) 1.34
Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation (2008) 1.32
Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler (2015) 1.30
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol (2012) 1.28
The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One (2013) 1.21
Impaired olfaction in mice lacking aquaporin-4 water channels. FASEB J (2008) 1.19
Pathogenic T cell responses against aquaporin 4. Acta Neuropathol (2011) 1.16
Functions of aquaporins in the eye. Prog Retin Eye Res (2008) 1.16
Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One (2011) 1.13
Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol (2010) 1.11
Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding. J Biol Chem (2011) 1.10
Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int (2012) 1.10
Fulminant demyelinating diseases. Neurohospitalist (2013) 1.10
Evidences for a leaky scanning mechanism for the synthesis of the shorter M23 protein isoform of aquaporin-4: implication in orthogonal array formation and neuromyelitis optica antibody interaction. J Biol Chem (2009) 1.09
Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol (2014) 1.08
Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia (2012) 1.08
Absence of cortical demyelination in neuromyelitis optica. Neurology (2010) 1.07
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07
Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol (2013) 1.06
Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol (2013) 1.05
Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflammation (2010) 0.98
B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol (2008) 0.98
Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler (2012) 0.97
Astrogliosis. Cold Spring Harb Perspect Biol (2014) 0.97
Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol (2012) 0.96
Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol (2009) 0.96
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) (2013) 0.96
Complexity and heterogeneity in demyelinating disease. Brain (2007) 0.95
Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG. Acta Neuropathol (2013) 0.95
Treatment of neuromyelitis optica: current debate. Ther Adv Neurol Disord (2008) 0.95
Brain-reactive antibodies and disease. Annu Rev Immunol (2013) 0.94
Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol (2013) 0.94
Is multiple sclerosis an autoimmune disease? Autoimmune Dis (2012) 0.94
Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol (2010) 0.93
The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Exp Neurol (2014) 0.93
C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol (2013) 0.92
Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci (2012) 0.92
Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions. BMC Neurol (2013) 0.91
Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol (2011) 0.91
Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol (2015) 0.91
Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis. Prog Neurobiol (2008) 0.91
Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J Autoimmun (2014) 0.91
Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int (2012) 0.90
Mechanisms of astrocyte-mediated cerebral edema. Neurochem Res (2014) 0.90
Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci (2013) 0.89
Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J Neuroinflammation (2014) 0.89
Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One (2013) 0.89
Brain Tissue Volumes and Perfusion Change with the Number of Optic Neuritis Attacks in Relapsing Neuromyelitis Optica: A Voxel-Based Correlation Study. PLoS One (2013) 0.88
The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol (2012) 0.87
White matter atrophy and cognitive dysfunctions in neuromyelitis optica. PLoS One (2012) 0.87
Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol (2009) 0.86
Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats. J Neurochem (2012) 0.86
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurol (2015) 0.86
Bilateral Internuclear Ophthalmoplegia in a Patient with Devic's Neuromyelitis Optica. Case Rep Neurol (2010) 0.86
Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability. PLoS One (2014) 0.85
Neuromyelitis optica spectrum disorders with multiple brainstem manifestations: a case report. Neurol Sci (2015) 0.85
Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury. Acta Neuropathol Commun (2014) 0.85
The treatment of neuromyelitis optica. J Neuroophthalmol (2014) 0.84
A neurodegenerative perspective on mitochondrial optic neuropathies. Acta Neuropathol (2016) 0.84
Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions. Neuroreport (2012) 0.84
B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Front Immunol (2015) 0.84
Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia (2014) 0.84
A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol (2011) 0.83
Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. Front Immunol (2015) 0.83
A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder. PLoS One (2014) 0.82
Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PLoS One (2013) 0.82
Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica. J Neurol (2012) 0.82
Immunotherapy of neuromyelitis optica. Autoimmune Dis (2013) 0.81
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet (2011) 3.16
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol (2012) 2.95
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Gray matter involvement in multiple sclerosis. Neurology (2007) 2.75
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61
Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain (2007) 2.58
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Disease-specific molecular events in cortical multiple sclerosis lesions. Brain (2013) 2.48
Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol (2006) 2.48
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Remyelination is extensive in a subset of multiple sclerosis patients. Brain (2006) 2.43
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci (2004) 2.35
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest (2006) 2.32
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A (2003) 2.30
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc (2004) 2.29
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26